Sort   by:  
 Page size 
UnknownComparing ARIA-E severity scales and effects of treatment management thresholds.
Not available
S-EPMC9716634 | biostudies-literature
UnknownBiomarker treatment effects in two phase 3 trials of gantenerumab.
Not available
S-EPMC11848197 | biostudies-literature
UnknownOcrelizumab exposure in relapsing-remitting multiple sclerosis: 10-year analysis of the phase 2 randomized clinical trial and its extension.
Not available
S-EPMC10827899 | biostudies-literature
UnknownChronic white matter lesion activity predicts clinical progression in primary progressive multiple sclerosis.
Not available
S-EPMC6736181 | biostudies-literature
UnknownA phase III randomized trial of gantenerumab in prodromal Alzheimer's disease.
Not available
S-EPMC5723032 | biostudies-literature
UnknownAssessing Amyloid Pathology in Cognitively Normal Subjects Using 18F-Flutemetamol PET: Comparing Visual Reads and Quantitative Methods.
Not available
S-EPMC6448465 | biostudies-literature
UnknownIn vivo assessment of neuroinflammation in progressive multiple sclerosis: a proof of concept study with [18F]DPA714 PET.
Not available
S-EPMC6234549 | biostudies-literature
UnknownVisual assessment of [18F]flutemetamol PET images can detect early amyloid pathology and grade its extent.
Not available
S-EPMC8175297 | biostudies-literature
UnknownSynSpine: an automated workflow for the generation of longitudinal spinal cord synthetic MRI data.
Not available
S-EPMC12753887 | biostudies-literature
UnknownHead-to-head comparison of tau PET tracers [18F]PI-2620 and [18F]RO948 in non-demented individuals with brain amyloid deposition: the TAU-PET FACEHBI cohort.
Not available
S-EPMC11603960 | biostudies-literature
Sort   by:  
 Page size